Royal London Asset Management
LEGN icon

Royal London Asset Management’s Legend Biotech LEGN Stock Holding History

Royal London Asset Management’s Portfolio LEGN Stock Details LEGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.17M Hold
75,000
– – ﹤0.01% 578
2026
Q1 		$1.36M Sell
75,000
-4,400
-6% -$83.9K ﹤0.01% 588
2025
Q4 		$1.73M Buy
79,400
+17,800
+29% +$510K ﹤0.01% 583
2025
Q3 		$2.01M Buy
61,600
+800
+1% +$29.5K ﹤0.01% 574
2025
Q2 		$2.16M Buy
60,800
+1,200
+2% +$38.9K ﹤0.01% 603
2025
Q1 		$2.02M Buy
+59,600
New +$2.14M ﹤0.01% 606

Other funds holding LEGN

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $832M AUM 32.38% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $30.6B AUM 61.81% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return
Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.56% 1-Year Est. Return

Royal London Asset Management's LEGN Position: Q2 2026 in Review

Royal London Asset Management held its Legend Biotech (LEGN) position steady in Q2 2026 at 75,000 shares worth $2.17M. The position accounts for ﹤0.01% of the portfolio, ranked #578.

Royal London Asset Management first reported a position in LEGN in Q1 2025 and has held it in 6 quarters since. 219 funds tracked by Wall St. Rank hold LEGN as of Q2 2026.

  • Royal London Asset Management held 75,000 shares of Legend Biotech worth $2.17M as of Q2 2026.
  • Royal London Asset Management left its Legend Biotech share count unchanged in Q2 2026.
  • Legend Biotech made up ﹤0.01% of Royal London Asset Management's portfolio in Q2 2026, its #578 holding.
  • Royal London Asset Management first reported a position in Legend Biotech in Q1 2025 and has held it in 6 quarters since.
  • 219 funds tracked by Wall St. Rank held Legend Biotech as of Q2 2026.

Based on Royal London Asset Management's 13F filing for Q2 2026, filed 13 Aug 2026.